Trial Search Results

Phase 1-2 of a CpG-Activated Whole Cell Vaccine Followed by Autologous Immunotransplant for MCL

Mantle Cell Lymphoma is a sub-type of Non-Hodgkin's Lymphoma which is generally considered incurable with current therapy. Our goal is to accrue 59 patients who receive an autologous vaccine against their individual lymphoma after undergoing stem cell transplantation. Our hope is that vaccination will prolong the time which patients will stay in remission from their disease.

Stanford is currently not accepting patients for this trial.

Lead Sponsor:

Ronald Levy

Collaborator: National Institutes of Health (NIH)

Intervention(s):

  • Biological: CpG-MCL vaccine, primed T-cells
  • Procedure: Autologous peripheral blood stem cell transplantation
  • Procedure: CT scan
  • Procedure: PET-CT scan
  • Drug: PF-3512676
  • Drug: Rituximab

Phase:

Phase 2

Eligibility


Inclusion Criteria (at time of enrollment):

   - Patients must be newly diagnosed with mantle cell lymphoma, have an accessible disease
   site for excisional biopsy or have sufficient peripheral blood tumor to leukapherese
   at least 1.5 x 109 lymphoma cells in a single session.

   - By standard clinical criteria, be medically appropriate to receive rituximab and
   standard induction chemotherapy and high-dose chemotherapy with AHCT.

   - Patients must be HIV negative.

   - ECOG performance status 0, 1, or 2 or Karnofsky performance scale 50-100%.

   - Patients must be capable of signing an informed consent.

Exclusion Criteria:

   - Patients who are currently taking immunosuppressive medications.

   - Patients with severe psychological or medical illness.

   - Pregnant or lactating women.

   - At the discretion of the principal investigator if he/she feels that the patient is
   unable to safely complete the study. Specifically, patients must be considered
   medically eligible to undergo standard high dose chemotherapy and autologous stem cell
   transplantation.

Ages Eligible for Study

21 Years - 70 Years

Genders Eligible for Study

All

Not currently accepting new patients for this trial

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
CCTO
650-498-7061
Not Recruiting